AstraZeneca has fronted $100 million to head deeper into the KRAS space, securing the rights to a clinical-stage, multitarget asset from China’s Jacobio Pharma. U.K.-based AstraZeneca has scored the ...
While Gracell Biotechnologies has ceased to exist as a publicly traded entity, the story continues for its former shareholders within the walls of pharmaceutical giant AstraZeneca. The narrative now ...
(RTTNews) - Jacobio Pharma (1167.HK) announced that it has entered into a strategic agreement with AstraZeneca (AZN, AZN.L, ZEG.DE, AZN.ST) for its proprietary Pan-KRAS inhibitor, JAB-23E73. Under the ...
For monetary values the unit of change is percent; for Gross Margin, Operating Margin and Tax rate the unit of change is percentage points. In the expense commentary above, the plus and minus bullets ...
BEIJING, SHANGHAI and BOSTON, Dec. 21, 2025 /PRNewswire/ -- Jacobio Pharma (1167.HK,) today announced that it has entered an agreement with AstraZeneca for its proprietary Pan-KRAS inhibitor JAB-23E73 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results